AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines

References

• Lazcano-PonceECMiquelJFMunozNEpidemiology and molecular pathology of gallbladder cancerCA Cancer J Clin20015134936411760569
   PubMed Web of Science ®Google Scholar
• RandiGFranceschiSLa VecchiaCGallbladder cancer worldwide: geographical distribution and risk factorsInt J Cancer20061181591160216397865
   PubMed Web of Science ®Google Scholar
• KreslJJSchildSEHenningGTAdjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinomaInt J Radiat Oncol Biol Phys20025216717511777635
   PubMed Web of Science ®Google Scholar
• MalikIAAzizZZaidiSHSethuramanGGemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladderAm J Clin Oncol20032617417712714891
   PubMed Web of Science ®Google Scholar
• ZhuAXHongTSHezelAFKoobyDACurrent management of gallbladder carcinomaOncologist20101516818120147507
   PubMed Web of Science ®Google Scholar
• ValleJWasanHPalmerDHCisplatin plus gemcitabine versus gemcitabine for biliary tract cancerN Engl J Med20103621273128120375404
   PubMed Web of Science ®Google Scholar
• FuruseJKasugaATakasuAKitamuraHNagashimaFRole of chemotherapy in treatments for biliary tract cancerJ Hepatobiliary Pancreat Sci20101933734122456744
   PubMed Web of Science ®Google Scholar
• FarisJEZhuAXTargeted therapy for biliary tract cancersJ Hepatobiliary Pancreat Sci20121932633622318523
   PubMed Web of Science ®Google Scholar
• MarinoDLeoneFCavalloniGCagnazzoCAgliettaMBiliary tract carcinomas: from chemotherapy to targeted therapyCrit Rev Oncol Hematol20138513614822809696
   PubMed Web of Science ®Google Scholar
• LubnerSJMahoneyMRKolesarJLReport of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a Phase II Consortium studyJ Clin Oncol2010283491349720530271
   PubMed Web of Science ®Google Scholar
• ZhuAXMeyerhardtJABlaszkowskyLSEfficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fuorodeoxyglucose PET with clinical outcome: a phase 2 studyLancet Oncol201011485419932054
   PubMed Web of Science ®Google Scholar
• BengalaCBertoliniFMalavasiNSorafenib in patients with advanced biliary tract carcinoma: a phase II trialBr J Cancer2010102687219935794
   PubMed Web of Science ®Google Scholar
• ChioreanEGRamasubbaiahRYuMPhase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101Oncologist2012171322210086
   PubMed Web of Science ®Google Scholar
• LeeJParkSHChangHMGemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 studyLancet Oncol20121318118822192731
   PubMed Web of Science ®Google Scholar
• GruenbergerBSchuellerJHeubrandtnerUCetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 studyLancet Oncol2010111142114821071270
   PubMed Web of Science ®Google Scholar
• LealPGarciaPSandovalAImmunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinomaArch Pathol Lab Med201313755255723544944
   PubMed Web of Science ®Google Scholar
• WuQKiguchiKKawamotoTTherapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse modelCancer Res2007673794380017440093
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov, a serive of the US National Institutes of Health Available from: http://clinicaltrails.gov/ct2/homeAccessed January, 2013
   Google Scholar
• National Cancer InstituteMK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by SurgeryClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated May 28, 2013]. Available from: http://clinicaltrials.gov/show/NCT01425879. NLM identifier: NCT01425879Accessed August 28, 2013
   Google Scholar
• GuertinDASabatiniDMThe pharmacology of mTOR inhibitionSci Signal20092pe2419383975
   PubMed Web of Science ®Google Scholar
• ZaytsevaYYValentinoJDGulhatiPEversBMmTOR inhibitors in cancer therapyCancer Lett20123191722261336
   PubMed Web of Science ®Google Scholar
• CarneroAThe PKB/AKT pathway in cancerCurr Pharm Des201016344420214616
   PubMed Web of Science ®Google Scholar
• HayNSonenbergNUpstream and downstream of mTORGenes Dev2004181926194515314020
   PubMed Web of Science ®Google Scholar
• HartmannBp70S6 kinase phosphorylation for pharmacodynamic monitoringClin Chim Acta20124131387139022531277
   PubMed Web of Science ®Google Scholar
• AltomareDAWangHQSkeleKLAKT and mTOR phospho-rylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growthOncogene2004235853585715208673
   PubMed Web of Science ®Google Scholar
• GaoNFlynnDCZhangZG1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cellsAm J Physiol Cell Physiol2004287C281C29115028555
   PubMed Web of Science ®Google Scholar
• GaoNZhangZJiangBHShiXRole of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancerBiochem Biophys Res Commun20033101124113214559232
   PubMed Web of Science ®Google Scholar
• MengQXiaCFangJRojanasakulYJiangBHRole of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathwayCell Signal2006182262227116839745
   PubMed Web of Science ®Google Scholar
• ZhouXTanMStone HawthorneVActivation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancersClin Cancer Res2004106779678815501954
   PubMed Web of Science ®Google Scholar
• KeckSGlencerACRugoHSEverolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancerFuture Oncol201281383139623148612
   PubMed Web of Science ®Google Scholar
• MabuchiSAltomareDACheungMRAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer modelClin Cancer Res2007134261427017634556
   PubMed Web of Science ®Google Scholar
• TaiSSunYLiuNCombination of RAD001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cellsMol Cancer Ther2012111320133122491797
   PubMed Web of Science ®Google Scholar
• HoughtonPJEverolimusClin Cancer Res2010161368137220179227
   PubMed Web of Science ®Google Scholar
• KeniryMParsonsRmTOR inhibition, the second generation: ATP-competitive mTOR inhibitor initiates unexpected receptor tyrosine kinase-driven feedback loopCancer Discov2011120320422586570
   PubMed Web of Science ®Google Scholar
• ChrestaCMDaviesBRHicksonIAZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activityCancer Res20107028829820028854
   PubMed Web of Science ®Google Scholar
• GiubellinoABullovaPNoltingSCombined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude miceEndocrinology201315464665523307788
   PubMed Web of Science ®Google Scholar
• HoltSVLogieADaviesBREnhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055)Cancer Res2012721804181322271687
   PubMed Web of Science ®Google Scholar
• SiniPJamesDChrestaCGuichardSSimultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cellsAutophagy2010655355420364113
   PubMed Web of Science ®Google Scholar
• GarciaPLealPAlvarezHConnective tissue growth factor immunohistochemical expression is associated with gallbladder cancer progressionArch Pathol Lab Med201313724525023368866
   PubMed Web of Science ®Google Scholar
• EstevaFJGuoHZhangSPTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancerAm J Pathol20101771647165620813970
   PubMed Web of Science ®Google Scholar
• ShoushaSOestrogen receptor status of breast carcinoma: Allred/H score conversion tableHistopathology20085334634718631198
   PubMed Web of Science ®Google Scholar
• LaplanteMSabatiniDMmTOR signaling at a glanceJ Cell Sci20091223589359419812304
   PubMed Web of Science ®Google Scholar
• DaiBKongYYYeDWActivation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristicsBJU Int20091041009101619389013
   PubMed Web of Science ®Google Scholar
• EgervariGMarkAHajduMMitotic lymphoma cells are characterized by high expression of phosphorylated ribosomal S6 proteinHistochem Cell Biol201113540941721424608
   PubMed Web of Science ®Google Scholar
• HeinonenHNieminenASaarelaMDeciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancerBMC Genomics2008934818652687
   PubMed Web of Science ®Google Scholar
• LangSAGaumannAKoehlGEMammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental modelInt J Cancer20071201803181017230506
   PubMed Web of Science ®Google Scholar
• MiyakawaMTsushimaTMurakamiHIncreased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissuesEndocr J200350778312733712
   PubMed Web of Science ®Google Scholar
• NoJHJeonYTParkIAActivation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancerGynecol Oncol201112181221276607
   PubMed Web of Science ®Google Scholar
• WangZZhengTWuQWangJWuCImmunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinomaNeoplasma20125913714122248270
   PubMed Web of Science ®Google Scholar
• XiaoLWangYCLiWSDuYThe role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarrayJ Exp Clin Cancer Res20092815220003385
   PubMed Web of Science ®Google Scholar
• ZhouHYWongASActivation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cellsEndocrinology20061472557256616469801
   PubMed Web of Science ®Google Scholar
• DharRBasuAConstitutive activation of p70S6 kinase is associated with intrinsic resistance to cisplatinInt J Oncol2008321133113718425342
   PubMed Web of Science ®Google Scholar
• KimEKKimHAKohJSPhosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancerBreast Cancer Res Treat2011126939921184268
   PubMed Web of Science ®Google Scholar
• LiuLZZhouXDQianGAKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathwayCancer Res2007676325633217616691
   PubMed Web of Science ®Google Scholar
• LeeDDoIGChoiKThe expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomasMod Pathol20122513113921874010
   PubMed Web of Science ®Google Scholar
• KoyamaSYoshiokaTMizushimaAEstablishment of a cell line (G-415) from a human gallbladder carcinomaGann1980715745757429092
   PubMedGoogle Scholar
• GhoshMKoikeNYanagimotoGEstablishment and characterization of unique human gallbladder cancer cell linesInt J Oncol2004241189119615067341
   PubMed Web of Science ®Google Scholar
• IpCKCheungANNganHYWongASp70S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cellsOncogene2011302420243221258406
   PubMed Web of Science ®Google Scholar
• CalvoFirst-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumorsJ Clin Oncol201230SupplAbstr 3005
   Google Scholar